ERBB2 and gastroesophageal junction adenocarcinoma: Fam-Trastuzumab deruxtecan EnhertuTM targets human epidermal growth factor receptor 2 (HER2) for the treatment of gastric cancer, breast cancer and gastroesophageal junction adenocarcinoma.